East Greenwich Township

Researchers are evaluating treatment options for adults with metastatic colorectal cancer that has a specific KRAS p.G12C mutation. The study compares progression-free survival in patients who have not received prior treatment. The trial is a Phase 3, multicenter, randomized, open-label study focusing on this particular mutation to improve outcomes in this patient group. Participants will receive one of two treatment combinations. One group will receive sotorasib (an oral drug), panitumumab (given via intravenous infusion every two weeks), and the FOLFIRI regimen—a combination of irinotecan, leucovorin, and 5-fluorouracil administered intravenously every two weeks. The other group will receive FOLFIRI with or without bevacizumab-awwb, which is also given intravenously every two weeks. Treatments continue according to the study schedule to assess effectiveness. Throughout the study, participants will be monitored for progression-free survival using standard criteria (RECIST v1.1) for up to about three years. Researchers will assess tumor response and disease progression to evaluate treatment effects. Participants will undergo regular evaluations to monitor organ function and overall health status during the study period.